Authors :
Heri Munajib; Wardah Rahmatul Islamiyah; J Eko Wahono
Volume/Issue :
Volume 6 - 2021, Issue 11 - November
Google Scholar :
http://bitly.ws/gu88
Scribd :
https://bit.ly/3y7DdYN
Abstract :
Valproic acid is commonly used in epilepsy
patients, both focal and generalized epilepsy, in many
cases, female epilepsy patients receiving valproic acid
therapy are not easy to replace valproic acid therapy
with other AEDs, therefore, when epilepsy patients are
faced with a program pregnancy often treatment with
valproic acid is unavoidable. The FDA's statement for
pregnant women with valproic acid is category X. Based
on this fact, how data and profiles of epilepsy patients in
Indonesia are still rarely found. supplementation of high
doses of folic acid and other minerals is very helpful in
minimizing the teratogenic effects of valproic acid for
infants for patients with epilepsy.
Objective: To report clinical and epidemiological the use
of valproic acid in pregnant women in the outpatient
clinic at DR. Soetomo Hospital between 2017-2020.
Methods: This is a retrospective study. All patients who
were treated in outpatient care unit in January 2017-
September 2020
Results: We obtained data from 2017-2020, 25 pregnant
women with a history of epilepsy, data obtained 25 of
them received valproic acid, 20 babies gave birth with
live babies and 5 babies died, IUGR 8 babies, congenital
malformations were found in 6 babies with 4 babies
having congenital malformations from pregnant women
with a history of epilepsy receiving valproic acid therapy.
Conclusion: Management Before Conception and
supplementation of Folic acid 1 mg/day for epileptic
patient during pregnancy can reduce the risk
malformation congenital in the baby
Keywords :
Epileptic patient with pregnancy, DR Soetomo Hospital, Valproic acid, Folic acid.
Valproic acid is commonly used in epilepsy
patients, both focal and generalized epilepsy, in many
cases, female epilepsy patients receiving valproic acid
therapy are not easy to replace valproic acid therapy
with other AEDs, therefore, when epilepsy patients are
faced with a program pregnancy often treatment with
valproic acid is unavoidable. The FDA's statement for
pregnant women with valproic acid is category X. Based
on this fact, how data and profiles of epilepsy patients in
Indonesia are still rarely found. supplementation of high
doses of folic acid and other minerals is very helpful in
minimizing the teratogenic effects of valproic acid for
infants for patients with epilepsy.
Objective: To report clinical and epidemiological the use
of valproic acid in pregnant women in the outpatient
clinic at DR. Soetomo Hospital between 2017-2020.
Methods: This is a retrospective study. All patients who
were treated in outpatient care unit in January 2017-
September 2020
Results: We obtained data from 2017-2020, 25 pregnant
women with a history of epilepsy, data obtained 25 of
them received valproic acid, 20 babies gave birth with
live babies and 5 babies died, IUGR 8 babies, congenital
malformations were found in 6 babies with 4 babies
having congenital malformations from pregnant women
with a history of epilepsy receiving valproic acid therapy.
Conclusion: Management Before Conception and
supplementation of Folic acid 1 mg/day for epileptic
patient during pregnancy can reduce the risk
malformation congenital in the baby
Keywords :
Epileptic patient with pregnancy, DR Soetomo Hospital, Valproic acid, Folic acid.